Moderna, Inc. Insider Trading

MRNA

Last 12 months

Insiders sold $81.6M and bought nothing on the open market.

99% of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Mar 2025.

Net open-market

−$81.6M

0 buys · 15 sales

Under a 10b5-1 plan

99%

of the value sold

Insiders who bought / sold

0 / 6

executives and directors

Last open-market buy

Mar 2025

Mar 3, 2025

Get an email when MRNA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 14 – 15	Stephen Hoge President	Sold10b5-1 plan 3 parts	78,369	$217.10 average	$17M	4.2%	Form 4
Sep 14 – 15	Stephen Hoge President	Sold10b5-1 plan 2 parts	80,575	$145.10 average	$11.7M	4.5%	Form 4
Sep 10	James M Mock Chief Financial Officer	Sold10b5-1 plan 2 parts	34,836	$134.49 average	$4.69M	37%	Form 4
Sep 1	Shannon Thyme Klinger Chief Legal Officer	Sold10b5-1 plan	3,471	$139.95	486K	4.4%	Form 4
Aug 5	Stephane Bancel Chief Executive Officer	Sold10b5-1 plan 4 parts	499,246	$57.52 average	$28.7M	3.1%	Form 4
Jul 15	Stephen Hoge President	Sold10b5-1 plan	53,336	$67.60	$3.61M	3.1%	Form 4
Jun 15	Stephen Hoge President	Sold10b5-1 plan	53,336	$51.37	$2.74M	3.1%	Form 4
Jun 4	Shannon Thyme Klinger Chief Legal Officer	Sold10b5-1 plan	3,471	$50.00	174K	4.5%	Form 4
May 21	Noubar Afeyan Director	SoldNo plan	9,263	$46.84	434K	0.1%	Form 4
May 15	Stephen Hoge President	Sold10b5-1 plan	53,336	$48.40	$2.58M	3.2%	Form 4
May 1	Abbas Hussain Director	Sold10b5-1 plan	5,682	$46.63	265K	32%	Form 4
Mar 2	Shannon Thyme Klinger Chief Legal Officer	Sold10b5-1 plan	13,885	$52.29	726K	19%	Form 4
Feb 23	Stephen Hoge President	Sold10b5-1 plan	160,009	$48.84	$7.81M	9.0%	Form 4
Dec 11, 2025	Noubar Afeyan Director	SoldNo plan	23,853	$29.49	703K	0.3%	Form 4
Dec 9, 2025	Abbas Hussain Director	Sold10b5-1 plan	504	$27.60	14K	25%	Form 4
Jun 11, 2025	Abbas Hussain Director	Sold10b5-1 plan	312	$28.00	9K	35%	Form 4
Mar 3, 2025	Stephane Bancel Chief Executive Officer	Bought 2 parts	160,314	$31.22 average	$5M	0.8%	Form 4
Mar 3, 2025	Paul Sagan Director	Bought	31,620	$31.76	$1M	6.8%	Form 4
Dec 9, 2024	Shannon Thyme Klinger Chief Legal Officer	Sold10b5-1 plan	529	$44.68	24K	2.5%	Form 4
Dec 3, 2024	Shannon Thyme Klinger Chief Legal Officer	Sold10b5-1 plan	112	$43.30	5K	0.6%	Form 4
Dec 3, 2024	Stephen Hoge President	Sold10b5-1 plan	314	$43.30	14K	<0.1%	Form 4
Nov 29, 2024	James M Mock Chief Financial Officer	Sold10b5-1 plan	1,420	$42.79	61K	11%	Form 4
Nov 29, 2024	Shannon Thyme Klinger Chief Legal Officer	Sold10b5-1 plan	1,418	$42.79	61K	6.7%	Form 4
Nov 29, 2024	Stephen Hoge President	Sold10b5-1 plan	291	$42.79	12K	<0.1%	Form 4
Nov 11, 2024	Stephen Hoge President	Sold10b5-1 plan	277	$46.10	13K	<0.1%	Form 4

Oct 14 – 1510b5-1 plan
Stephen Hoge
President · sold 78,369 at avg $217.10
$17M
4.2% of stake
Sep 14 – 1510b5-1 plan
Stephen Hoge
President · sold 80,575 at avg $145.10
$11.7M
4.5% of stake
Sep 1010b5-1 plan
James M Mock
Chief Financial Officer · sold 34,836 at avg $134.49
$4.69M
37% of stake
Sep 110b5-1 plan
Shannon Thyme Klinger
Chief Legal Officer · sold 3,471 at $139.95
486K
4.4% of stake
Aug 510b5-1 plan
Stephane Bancel
Chief Executive Officer · sold 499,246 at avg $57.52
$28.7M
3.1% of stake
Jul 1510b5-1 plan
Stephen Hoge
President · sold 53,336 at $67.60
$3.61M
3.1% of stake
Jun 1510b5-1 plan
Stephen Hoge
President · sold 53,336 at $51.37
$2.74M
3.1% of stake
Jun 410b5-1 plan
Shannon Thyme Klinger
Chief Legal Officer · sold 3,471 at $50.00
174K
4.5% of stake
May 21No plan
Noubar Afeyan
Director · sold 9,263 at $46.84
434K
0.1% of stake
May 1510b5-1 plan
Stephen Hoge
President · sold 53,336 at $48.40
$2.58M
3.2% of stake
May 110b5-1 plan
Abbas Hussain
Director · sold 5,682 at $46.63
265K
32% of stake
Mar 210b5-1 plan
Shannon Thyme Klinger
Chief Legal Officer · sold 13,885 at $52.29
726K
19% of stake
Feb 2310b5-1 plan
Stephen Hoge
President · sold 160,009 at $48.84
$7.81M
9.0% of stake
Dec 11, 2025No plan
Noubar Afeyan
Director · sold 23,853 at $29.49
703K
0.3% of stake
Dec 9, 202510b5-1 plan
Abbas Hussain
Director · sold 504 at $27.60
14K
25% of stake
Jun 11, 202510b5-1 plan
Abbas Hussain
Director · sold 312 at $28.00
9K
35% of stake
Mar 3, 2025
Stephane Bancel
Chief Executive Officer · bought 160,314 at avg $31.22
$5M
0.8% of stake
Mar 3, 2025
Paul Sagan
Director · bought 31,620 at $31.76
$1M
6.8% of stake
Dec 9, 202410b5-1 plan
Shannon Thyme Klinger
Chief Legal Officer · sold 529 at $44.68
24K
2.5% of stake
Dec 3, 202410b5-1 plan
Shannon Thyme Klinger
Chief Legal Officer · sold 112 at $43.30
5K
0.6% of stake
Dec 3, 202410b5-1 plan
Stephen Hoge
President · sold 314 at $43.30
14K
<0.1% of stake
Nov 29, 202410b5-1 plan
James M Mock
Chief Financial Officer · sold 1,420 at $42.79
61K
11% of stake
Nov 29, 202410b5-1 plan
Shannon Thyme Klinger
Chief Legal Officer · sold 1,418 at $42.79
61K
6.7% of stake
Nov 29, 202410b5-1 plan
Stephen Hoge
President · sold 291 at $42.79
12K
<0.1% of stake
Nov 11, 202410b5-1 plan
Stephen Hoge
President · sold 277 at $46.10
13K
<0.1% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch MRNA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with MRNA

CompareIntrinsic value

EXELExelixis Inc.

$72.75+0.61%97

HALOHalozyme Therapeutics Inc.

$130.34+1.34%66

NBIXNeurocrine Biosciences Inc.

$167.21+1.43%85

TECHBio-Techne Corporation

$72.73+0.10%52

BCRXBioCryst Pharmaceuticals Inc.

$8.24-3.85%64

RGENRepligen Corporation

$178.20-0.04%35

NVAXNovavax Inc.

$10.65+10.02%10

TARSTarsus Pharmaceuticals Inc.

$69.07-4.91%55

Held by ETFs

MRNA is in 234 US ETFs. The largest of them, with MRNA's weight in each:

Spot a number that looks wrong? Check it in MRNA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing MRNA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.